Eledon Pharmaceuticals (ELDN) Total Non-Current Liabilities (2015 - 2026)
Eledon Pharmaceuticals posted quarterly Total Non-Current Liabilities of $15.8 million for Q1 2026, up 32.78% year-on-year from $11.9 million in Q1 2025, and down 23.94% on a QoQ basis from $20.8 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 12 years of Total Non-Current Liabilities data on file, last reported at $15.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 32.78% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $15.8 million (up 32.78% YoY), and the FY2025 full-year result was $20.8 million, up 44.54% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $15.8 million, down from $20.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $20.8 million in Q4 2025 and bottomed at $4.7 million in Q3 2023.
- The 5-year median for Total Non-Current Liabilities is $11.9 million (2025), against an average of $11.6 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities sank 34.41%; it then soared 207.48% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $8.6 million in 2022, then tumbled by 34.41% to $5.6 million in 2023, then surged by 155.0% to $14.4 million in 2024, then soared by 44.54% to $20.8 million in 2025, then decreased by 23.94% to $15.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $15.8 million (Q1 2026), $20.8 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | 15.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.83 Mn |
| Dec 31, 2025 | 20.81 Mn |
| Sep 30, 2025 | 16.86 Mn |
| Jun 30, 2025 | 16.37 Mn |
| Mar 31, 2025 | 11.92 Mn |
| Dec 31, 2024 | 14.40 Mn |
| Sep 30, 2024 | 14.56 Mn |
| Jun 30, 2024 | 8.16 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 6.84 Mn |
| Dec 31, 2022 | 8.61 Mn |
| Dec 31, 2021 | 6.55 Mn |
| Dec 31, 2020 | 6.59 Mn |
| Dec 31, 2019 | 1.47 Mn |
| Dec 31, 2018 | 2.53 Mn |
| Dec 31, 2017 | 1.44 Mn |
| Sep 30, 2017 | 94,000.00 |
| Jun 30, 2017 | 245,000.00 |
| Mar 31, 2017 | 48,000.00 |
| Dec 31, 2016 | 84,000.00 |
| Sep 30, 2016 | 120,000.00 |
| Jun 30, 2016 | 156,000.00 |
| Mar 31, 2016 | 6.18 Mn |
| Dec 31, 2015 | 88,000.00 |
| Sep 30, 2015 | 5.66 Mn |
| Jun 30, 2015 | 4.65 Mn |